Similar articles

• [Optimizing treatment of advanced urologic malignancies].

  Heidenreich A, Ohlmann CH, Ozgür E, Pfister D, Sahi D, Thüer D, Engelmann UH. Heidenreich A, et al. Urologe A. 2007 Sep;46(9):1278-84. doi: 10.1007/s00120-007-1396-4. Urologe A. 2007. PMID: 17628781 German. No abstract available.
• Gene therapy--the future is here: a guide to the practicing urologist.

  Naitoh J, Belldegrun A. Naitoh J, et al. Urology. 1998 Mar;51(3):367-80. doi: 10.1016/s0090-4295(97)00624-9. Urology. 1998. PMID: 9510338 Review. No abstract available.
• [Response criteria for urological cancer treatment].

  [No authors listed] [No authors listed] Nihon Hinyokika Gakkai Zasshi. 1992 Apr;83(4):447-72. Nihon Hinyokika Gakkai Zasshi. 1992. PMID: 1593826 Japanese. No abstract available.
• The role of methylation in urological tumours.

  van der Heijden AG. van der Heijden AG. Arch Esp Urol. 2013 Jun;66(5):432-9. Arch Esp Urol. 2013. PMID: 23793761 Review.
• The systemic therapy of urologic cancer.

  Marsh JC. Marsh JC. Conn Med. 1980 Apr;44(4):217-24. Conn Med. 1980. PMID: 7371401 No abstract available.